BiomimX
Developing beating organs-on-chip platforms as in vitro pre-clinical models to improve the drug development process.
- dt and ls
- biotechnology
- horizon europe
- woman founder
- spinout
- eit ecosystem
- drug development
- cardiology and cardiovascular
- eit health
- health it
- eit supernovas
- ai drug discovery
- techbio
- seal of excellence ec
- health diagnostics
- techbio drug discovery
- headstart (eit health)
- eic
- health information
- microfluidics
- regenerative medicine
- degenerative diseases
- headstart 2018 (eit health)
- organ-on-chip
- rare diseases
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
€1.5m | Grant | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 231 % | 185 % | 101 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
BiomimX, founded in 2017, is a company at the forefront of preclinical drug development. The company specializes in the development of advanced 3D organ-on-a-chip (OoC) platforms, which are micro-engineered systems that mimic the complex structures and functions of human organs.
These OoC platforms, often referred to as "human mini-organs on chips," provide a more physiologically relevant environment for testing the efficacy and toxicity of new drug candidates compared to traditional 2D cell cultures and animal models. By creating more predictive and reliable in-vitro models, BiomimX aims to accelerate the drug discovery process, reduce the high costs associated with preclinical research, and decrease the reliance on animal testing.
The company's technology is particularly focused on creating dynamic, 3D beating heart-on-a-chip models, which are instrumental for cardiovascular drug discovery and safety pharmacology. BiomimX serves the pharmaceutical and biotechnology industries, providing them with tools to make more informed decisions earlier in the drug development pipeline.
Keywords: organ-on-a-chip, 3D cell culture, in-vitro models, preclinical testing, drug discovery, pharmaceutical, biotechnology, microfluidics, toxicology, personalized medicine